Table 1 Relationship between AVEN expression and clinical characteristics in lung adenocarcinoma.
Characteristics | Low expression of AVEN | High expression of AVEN | P value |
|---|---|---|---|
n | 269 | 270 | Â |
Pathologic T stage, n (%) | Â | Â | 0.018 |
 T1 | 102 (19%) | 74 (13.8%) |  |
 T2 | 139 (25.9%) | 153 (28.5%) |  |
 T3&T4 | 27 (5%) | 41 (7.6%) |  |
Pathologic N stage, n (%) | Â | Â | 0.003 |
 N0 | 190 (36.3%) | 160 (30.6%) |  |
 N1 | 42 (8%) | 55 (10.5%) |  |
 N2&N3 | 26 (5%) | 50 (9.6%) |  |
Pathologic M stage, n (%) | Â | Â | 0.237 |
 M0 | 176 (45.1%) | 189 (48.5%) |  |
 M1 | 9 (2.3%) | 16 (4.1%) |  |
Pathologic stage, n (%) | Â | Â | 0.005 |
 Stage I | 167 (31.5%) | 129 (24.3%) |  |
 Stage II | 58 (10.9%) | 67 (12.6%) |  |
 Stage III | 32 (6%) | 52 (9.8%) |  |
 Stage IV | 9 (1.7%) | 17 (3.2%) |  |
Primary therapy outcome, n (%) | Â | Â | 0.054 |
 PD | 26 (5.8%) | 45 (10%) |  |
 SD | 22 (4.9%) | 16 (3.6%) |  |
 PR | 2 (0.4%) | 4 (0.9%) |  |
 CR | 176 (39.2%) | 158 (35.2%) |  |
Gender, n (%) |  |  | < 0.001 |
 Female | 165 (30.6%) | 124 (23%) |  |
 Male | 104 (19.3%) | 146 (27.1%) |  |
Age, n (%) | Â | Â | 0.334 |
 <= 65 | 122 (23.5%) | 135 (26%) |  |
 > 65 | 136 (26.2%) | 127 (24.4%) |  |
Number pack years smoked, n (%) | Â | Â | 0.133 |
 < 40 | 103 (27.9%) | 85 (23%) |  |
 >= 40 | 85 (23%) | 96 (26%) |  |
OS event, n (%) |  |  | < 0.001 |
 Alive | 194 (36%) | 153 (28.4%) |  |
 Dead | 75 (13.9%) | 117 (21.7%) |  |
DSS event, n (%) |  |  | < 0.001 |
 No | 213 (42.3%) | 170 (33.8%) |  |
 Yes | 44 (8.7%) | 76 (15.1%) |  |
PFI event, n (%) | Â | Â | 0.010 |
 No | 171 (31.7%) | 142 (26.3%) |  |
 Yes | 98 (18.2%) | 128 (23.7%) |  |
